glp 1 agonist with dpp 4 inhibitor Mechanism of action for GIP, GLP-1 analogues and DPP4 inhibitors in Comparison of GLP-1 receptor agonists
Description
doi: 10.1111/dom.16275 37 SantiniSVionnetNPasquierJGonzalez-RodriguezEFragaMPitteloudNet al

The future of NAFLD treatment seems exciting and challenging and has the potential to include more personalized and targeted therapeutic approaches, while issues concerning their safety must be thoroughly recorded and appropriately evaluated [42, 43, 138, 144146].

Blood sugar improvements often begin within the first week

This review highlights key clinical considerations across reproductive stages, emphasizes the primacy of human exposure data where available, and identifies critical evidence gaps requiring future prospective study
Diabetologia 53: 22332240

GLP-1 based therapies: clinical implications for gastroenterologists